TITLE

δEF1 Down-Regulates ER-α Expression and Confers Tamoxifen Resistance in Breast Cancer

AUTHOR(S)
Shaocong Guo; Yaqing Li; Qi Tong; Feng Gu; Tianhui Zhu; Li Fu; Shuang Yang
PUB. DATE
December 2012
SOURCE
PLoS ONE;Dec2012, Vol. 7 Issue 12, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Resistance to tamoxifen therapy represents a major barrier to the successful treatment of breast cancer, where a loss of or reduced ER-α level is considered a primary mechanism. Understanding how ER-α expression is regulated would provide insights into new intervention points to overcome tamoxifen resistance. In this study, we report that the expression of δEF1 is up-regulated by 17β-estradiol (E2) in MCF-7 cells in an ER-α-dependent manner, through either PI3K or NF-κB pathway. Ectopic expression of δEF1 in turn repressed ER-α transcription by binding to the E2-box on the ER-α promoter. At the tissue level of breast cancer, there is a strong and inverse correlation between the expression levels of δEF1 and ER-α. In MCF-7 cells, an elevated expression of δEF1 made the cells less sensitive to tamoxifen treatment, whereas overexpression of ER-α compromised the effects of δEF1 and restored the sensitivity. Also, depletion of δEF1 by RNA interference in MDA-MB-231 cells restored the expression of ER-α and tamoxifen sensitivity. In conclusion, we have identified an important role of δEF1 in the development of tamoxifen resistance in breast cancer. Inhibiting δEF1 to restore ER-α expression might represent a potential therapeutic strategy for overcoming endocrine resistance in breast cancer.
ACCESSION #
84710655

 

Related Articles

  • Delivering tamoxifen within solid lipid nanoparticles. Abbasalipourkabir, Roghayeh; Salehzadeh, Aref; Abdullah, Rasedee // Pharmaceutical Technology Europe;Apr2011, Vol. 23 Issue 4, p22 

    Solid lipid nanoparticles (SLNs) have been proposed as an alternative colloidal drug-delivery system for water-soluble drugs. The aim of this study was to prepare and characterise physiochemically and biologically tamoxifen-loaded SLNs to evaluate their effectiveness as a drug-delivery system to...

  • Pfizer presents data supporting its breast cancer drug.  // PharmaWatch: Cancer;April 2004, Vol. 3 Issue 4, p17 

    Discusses the results from a Pfizer-sponsored study which indicated that post-menopausal breast cancer patients who switched from tamoxifen to Aromasin had a significantly reduced chance of recurrence and increased disease-free survival compared to patients who remained on tamoxifen. Challenge...

  • Breast Cancer Patients Switched to Pfizer's Aromasin Were More Likely to Remain Cancer Free, Study Shows; Results From Pfizer-Sponsored Study Challenge Standard Tamoxifen Therapy.  // Ascribe Newswire: Medicine;3/22/2004, p22 

    Post-menopausal breast cancer patients who switched from tamoxifen to Aromasin had a significantly reduced chance of recurrence and increased disease-free survival compared to patients who remained on tamoxifen, according to new data published in the March 22, 2004 issue of the "New England...

  • Medical treatment of early breast cancer. IV: neoadjuvant treatment. Smith, Ian E.; Chua, Susan // BMJ: British Medical Journal (International Edition);1/28/2006, Vol. 332 Issue 7535, p223 

    The article reports on neoadjuvant treatment of breast cancer, which aims to downstage large cancers before operation to reduce the use of mastectomy. In a research setting, the primary tumor is used as a measure of responsiveness to treatment. The immediate preoperative Arimidex compared with...

  • Contralateral Breast Cancer and Thromboembolic Events in African American Women Treated With Tamoxifen. McCaskill-Stevens, Worta; Wilson, John; Bryant, John; Mamounas, Eleftherios; Garvey, Lori; James, Joan; Cronin, Walter; Wickerham, D. Lawrence // JNCI: Journal of the National Cancer Institute;12/1/2004, Vol. 96 Issue 23, p1762 

    Background: Information about breast cancer treatment and prevention in African American women is scant, and recommendations for therapy from clinical trials for breast cancer are based primarily on data obtained from white women. Methods: We compared the effects of tamoxifen on risk of...

  • Tamoxifen and TRAIL synergistically induce apoptosis in breast cancer cells. Lagadec, C.; Adriaenssens, E.; Toillon, R. A.; Chopin, V.; Romon, R.; Van Coppenolle, F.; Hondermarck, H.; Le Bourhis, X. // Oncogene;2/28/2008, Vol. 27 Issue 10, p1472 

    Tamoxifen (TAM), is widely used as a single agent in adjuvant treatment of breast cancer. Here, we investigated the effects of TAM in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in estrogen receptor-α (ER-α)-positive and -negative breast cancer cells....

  • Increasing Tamoxifen Dose in Breast Cancer Patients Based on CYP2D6 Genotypes and Endoxifen Levels: Effect on Active Metabolite Isomers and the Antiestrogenic Activity Score. Barginear, M. F.; Jaremko, M.; Peter, I.; Yu, C.; Kasai, Y.; Kemeny, M.; Raptis, G.; Desnick, R. J. // Clinical Pharmacology & Therapeutics;Oct2011, Vol. 90 Issue 4, p605 

    Tamoxifen (Tam), the major drug for estrogen receptor (ER)-positive breast cancer, is converted to its active metabolites, Z- and Z′-endoxifen and 4-OH-Tam isomers, primarily by cytochrome P450 CYP2D6. In 117 patients taking 20 mg/day of Tam, we determined CYP2D6 genotypes and measured the...

  • tamoxifen.  // Royal Society of Medicine: Medicines;2002, p522 

    The article presents information on the sex hormone antagonist tamoxifen which is an anti-estrogen that antagonizes the natural estrogen present in the body and can be useful in treating infertility in women. It can also be used as an anticancer drug in the treatment of existing...

  • AIB1 is a predictive factor for tamoxifen response in premenopausal women. Alkner, S.; Bendahl, P.-O.; Grabau, D.; Lövgren, K.; Stål, O.; Ryden, L.; Ferno, M. // Annals of Oncology;Feb2010, Vol. 21 Issue 2, p238 

    Background: Clinical trials implicate the estrogen receptor (ER) coactivator amplified in breast cancer 1 (AIB1) to be a prognostic and a treatment-predictive factor, although results are not unanimous. We have further investigated this using a controlled randomised trial of tamoxifen versus...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics